AstraZeneca shares tumble after heart drug trial fails
read at Endpoints ↗Negative readoutNegative
AstraZeneca's stock fell in early trading on Thursday after the company disclosed that its experimental heart disease therapy, developed with Ionis Pharmaceuticals, did not meet primary endpoints in a late‑stage study.
The antisense drug, known as Wainua, was aimed at treating a specific cardiac condition, and the unexpected negative outcome represents a setback for the partnership.
The failure is likely to prompt both firms to reassess their cardiovascular pipelines, and investors reacted by pushing the share price lower.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Updated: AstraZeneca sinks on unexpected heart drug trial failure”
read at Endpoints ↗82 words · retrieved Jul 9
comments(0)
5-min edit window · permanent after that